New Launch23 Sept 2025, 02:13 pm
Marksans Pharma's UK Subsidiary, Relonchem, Receives Marketing Authorisation from UK MHRA
AI Summary
Marksans Pharma Ltd's subsidiary, Relonchem Limited in UK, has received marketing authorisation for its products from the UK MHRA. The products include Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets.
Key Highlights
- Marksans Pharma's UK subsidiary, Relonchem, receives marketing authorisation from UK MHRA
- Authorisation given for Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets
- Marksans Pharma Ltd's wholly owned subsidiary in UK, Relonchem Limited, is the recipient of the authorisation